Full-Time
People & Communications Support Graduate
HR position
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Entry
Salt, Girona, Spain
In Person
- Bachelor’s degree in Psychology, Labor Relations, Communications, Human Resources or a related field
- Excellent written and verbal communication skills
- Fluent in English
- Availability to start on October 1st, 2025
- Own vehicle required to access the worksite
- Participate in planning, developing of HR projects and process
- Provide support to specific HR process on industrial site, such as recruitment of industrial position, performance and support manager on shopfloor.
- Support labor relation process and relationship on the industrial site
- Put in place action plan designed to minimize the impact of absenteeism on the industrial site.
- Works closely with HRBPs, Employee Relations, employees and management.
- Responsible of keeping update all the data system (org chart on workday, salaries, hierarchies, grading etc)
- Work closely with Employee Experience team to prepare and consolidate information requested by HR team
- Participate and keep updated all budget and trend for HR controlling
- Manage and maintain updated communication channels needed in the plant
- Coordinate the consolidation of information & content and generate final materials
- Design and execute communication campaigns to support decisions and action plans carried out at the plant
- Provide support in the preparation of events and meetings
- Write and adapt content for external plant communications
Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing extensive research and development to create new therapies and improve existing ones, ensuring they meet the needs of patients and healthcare providers. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse portfolio that includes prescription medicines, over-the-counter products, and vaccines. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
- The FDA approval of Dupixent addresses a large unmet need in dermatology.
- Sanofi's 20% profit growth in Q1 2025 highlights effective market strategies.
What critics are saying
- Increased competition in immunology could impact Sanofi's market share.
- Potential delays in regulatory approvals may affect new product launches.
- Integration challenges from acquisitions could disrupt operations and delay synergies.
What makes Sanofi unique
- Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
- The company leverages strategic partnerships to enhance its innovative treatment pipeline.
- Sanofi's global reach allows it to navigate diverse regulatory environments effectively.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.
Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750...
New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...